As a multispecialty, clinically oriented organization of ultrasound specialists, the AIUM participates closely in developments that it identifies as essential for the medical community to improve patient care. The introduction of ultrasound contrast media in the mid-1990s has already revolutionized the practice of ultrasound imaging in those countries where they are available. In particular, it has been established that ultrasound imaging performed with contrast enhancement (contrast-enhanced ultrasound [CEUS] ) allows for accurate characterization and detection of focal liver lesions, which often are not possible with conventional ultrasound imaging. Numerous single-and multi-center investigations of CEUS have shown that both detection and characterization of liver masses are comparable to those achieved with contrast-enhanced computed tomographic (CT) or magnetic resonance (MR) scans. Ultrasound imaging performed with contrast enhancement is clearly superior to ultrasound imaging performed alone. In fact, the lack of specificity for the confident diagnosis of liver masses with ultrasound imaging alone is so well recognized that, in most cases, the identification of a liver mass on ultrasound imaging provokes confirmatory imaging with either a CT or an MR scan. In patients at risk for hepatocellular carcinoma or metastases, there is recognition that confirmation of all masses identified on ultrasound imaging with either CT or MR scans is essential.
In addition to the lack of specificity for ultrasound-based diagnosis of liver masses, ultrasound-based detection of focal liver masses can be poor, especially in patients at risk for metastatic liver disease. Although some metastases may be easily seen on ultrasound imaging because they are either echogenic or hypoechoic relative to the liver parenchyma, many others have backscatter similar to that of the background liver. These so-called "isoechoic" or "invisible masses" have backscatter that is identical to that of the adjacent normal parenchyma, and they are difficult if not impossible to detect without the aid of ultrasound contrast. Studies have shown that these masses can be identified with a sensitivity comparable to that of contrastenhanced CT or MR imaging by the addition of ultrasound contrast agents. A review of the world literature on the efficacy of CEUS imaging compared with non-CEUS imaging for the detection and characterization of liver lesions is documented in "Appendix A."
A key element in the evolution of medical imaging technology has been the development from plain imaging to techniques enhanced by intravascular contrast agents. In many countries outside the United States, it is no longer considered sufficient to perform only non-CEUS imaging of the liver for detection and characterization of focal liver masses.
It is the AIUM's considered opinion that the lack of availability of CEUS for noncardiac imaging in the United States hinders the delivery of optimal diagnostic imaging services to our patients. As a result, we lag behind the rest of the world in the appropriate and proven uses of contrast agents for liver mass diagnosis and detection. The AIUM believes that this is having an adverse impact on clinical care in the United States.
Therefore, pursuant to the request by the US Food and Drug Administration (FDA), the AIUM proposes the following recommendations for consideration for future CEUS clinical trials.
I. Appropriate End Points for Assessment of Ultrasound Contrast Efficacy in the Liver
Ultrasound imaging of the liver in the United States is currently performed without contrast media. Contrast media are intended to improve lesion conspicuity for increased lesion detection sensitivity and/or to improve lesion characterization for increased diagnostic specificity. Improved detection sensitivity and/or diagnostic specificity when a contrast agent is used compared with conventional non-CEUS imaging should be sufficient to establish efficacy for approval. A recommended trial, therefore, should compare the non-CEUS imaging performance with the CEUS imaging performance against an accepted truth standard. The basis for FDA approval should be a significant improvement of CEUS over non-CEUS imaging. The AIUM believes that there are situations in which it is clearly obvious that the improved diagnostic/prognostic information achieved with CEUS imaging is clinically useful. These should be considered an adequate basis for FDA approval. Possible beneficial outcomes from the use of CEUS may include, but are not limited to, the following:
• Improved characterization of focal liver masses with CEUS imaging, such as to determine whether a focal liver mass is benign or malignant, compared with non-CEUS imaging.
• Improved ability to detect focal liver masses with CEUS imaging. • A reduction in referral for further workup using other imaging or diagnostic procedures.
• Assessment of therapeutic response.
II. Examination Procedures
A. The contrast agent should be prepared and administered according to the manufacturer's recommendations. B. Equipment should be quality controlled and capable of performing CEUS imaging as described in section III, "Equipment Criteria and Variables." C. Scans should be performed by qualified personnel as described in section V, "Training."
D. Baseline (noncontrast) ultrasound imaging should include representative images of the liver and any visible hepatic lesions. E. Contrast-enhanced ultrasound image data should be acquired and stored as a real-time digital data set from before contrast agent injection until achievement of the diagnostic effect as determined for each agent/protocol.
III. Equipment Criteria and Variables
A. Contrast studies of the liver require contrast-specific imaging modes that operate at a low mechanical index (MI). B. The trial protocol should specify the performance requirements of high-end systems for the study. C. Manufacturers of ultrasound equipment have products with specifically designed presets for CEUS imaging of the liver, and these should be used. D. Machine presets should include system parameters as well as settings that can be controlled by the user. Careful limits should be placed on the ability of the user to adjust controls once the preset has been selected. Considerations for specific settings should include the following:
1. Nonlinear Contrast Imaging Mode. As real-time imaging is a key requirement for liver imaging, a low-MI mode is needed that does not disrupt the contrast microbubbles. The mode detects the echo returning from the bubbles and suppresses the echoes from the tissue containing them. Nonlinear modes that meet these requirements usually employ multiple pulses, which are modulated in phase and/or amplitude. These schemes go under various commercial names. A machine that does not offer such a mode is not suitable for contrast imaging. Examples of suitable modes in some systems currently on the market are listed in "Appendix B." 2. Available Transducers. The appropriate transducer for contrast imaging of the liver must be specified in the protocol.
3. Mechanical Index. The MI should be maintained at a level that minimizes microbubble loss in the anatomic region of interest. The actual exposure of the agent to the ultrasound beam varies with anatomic conditions, so the fixed setting of MI provided by the preset should be used as a starting point. The displayed MI is an estimate only; actual microbubble loss is determined by factors other than the MI alone. Therefore, the appropriate MI setting should be determined separately for each ultrasound scanner model and the body habitus of each specific patient. In general, the lowest MI consistent with a successful examination should be used. 4. Operating Frequency. The operating frequency for a given machine should be specified in the protocol. In general, contrast-specific nonlinear imaging modes are more sensitive at lower operating frequencies, which also offer better penetration but lower spatial resolution. Thus, sensitivity to the agent is added to the trade-off between resolution and penetration. 5. Multiple Modes. The user must be able to view both the noncontrast and contrast images because contrast-specific imaging modes suppress the echo from tissue. Machines that offer simultaneous noncontrast and contrast-specific images are preferred. The noncontrast image MI should be controlled so that no inadvertent microbubble loss occurs. 6. Line Density/Frame Rate. In general, the lower the exposure of microbubbles to ultrasound, the lower the rate of microbubble loss. Reducing line density and frame rate to the minimum consistent with diagnostic interpretation is recommended. Zoom or magnification modes should not be used. E. Trial designers should work with system manufacturers to standardize machine presets for each trial. F. Contrast-enhanced ultrasound modes should be well documented, with setup algorithms and work flow guides (see "Appendix B"). A step-by-step procedure for use of the system during the examination should be specified. G. While the technology for CEUS modes may continue to evolve, it is recommended that the technology for an individual trial should not be changed once the trial begins.
IV. Safety
In medical procedures, considerations should always be given to comparing the risks with the benefits to the patient. Clinical utility from improved diagnostic image information has been demonstrated with ultrasound contrast agents. Approval for the use of such agents in the United States and internationally has resulted in numerous examinations using a variety of agents (millions of doses). The general safety record of ultrasound contrast agents has been quite good, as discussed below. It is the responsibility of the ultrasound community to help maintain the safety record of ultrasound imaging and determine any risks associated with the methods used. Several aspects need to be considered:
General Safety Record of Ultrasound Imaging
Medical ultrasound imaging has been used since the 1950s. Since its introduction, this modality has been considered one of the safest methods of medical imaging. As indicated by the general clinical safety statement from the AIUM (see "Clinical Safety" at http://www.aium.org/ publications/statements/statements.asp), there are no confirmed harmful biological effects in patients from exposure to ultrasound energy at levels commonly used for diagnostic imaging. The possibility exists that biological effects may be identified in the future, but the benefits of the prudent use of ultrasound outweigh the risk, if any, that may be present. Although this statement has largely been considered in terms of conventional non-CEUS imaging, it is important to remember that the same assessment should be made when weighing benefits and risks in clinical CEUS imaging. In the absence of specific evidence of risk and with demonstrated patient benefit, the prudent use of contrast agents should be appropriate. Additionally, when the use of a contrast agent provides significant diagnostic information, not performing such a procedure may also increase medical risk to the patient.
Potential for Bioeffects
The currently approved ultrasound contrast agents use microbubbles to produce the added contrast provided by the agent. Contrast agents are a relatively new addition to ultrasound imaging, and identifying potential risks is an ongoing process. There is a wealth of theoretical and experimental knowledge about the interactions of microbubbles and ultrasound energy. This knowledge results from a considerable number of investigations on bubble-ultrasound interactions, including cavitation activity that can have enough energy to induce bioeffects. There have been several studies in vitro and in animal models that have shown potential bioeffects. Many of these animal studies have been related to ultrasound exposure of cardiac tissue in the presence of microbubble contrast agents. [3] [4] [5] [6] [7] [8] [9] [10] One early study in humans reported induction of premature ventricular contractions (PVCs) using a high MI and end-systolic triggering. 11 However, other studies using different exposure conditions did not find an increased frequency of PVCs. [12] [13] [14] [15] The induction of PVCs in humans appears to require a relatively high MI, imaging at a specific point in the cardiac cycle, and substantial contrast agent filling of the cardiac tissue.
In terms of noncardiac studies, some animal studies have been positive for effects, 7, [16] [17] [18] [19] but the relationship to the clinical situation has not been clearly established. Of particular relevance to cancer imaging, 1 study 20 did not find an enhancement of metastatic spread in mouse melanoma tumors using diagnostic levels of ultrasound in the presence of contrast agents. The identification of any potential biological effect must be placed in context. The likelihood of the effect in the clinical situation and the clinical significance of such effects should be assessed.
To the credit of the ultrasound community, there have been very active researchers who have carefully considered mechanisms for biological effects of ultrasound. These individual researchers and collective activities such as those of the Bioeffects Committee of the AIUM have helped identify potential effects that have been explored further. These efforts should continue as part of maintaining the established reputation of diagnostic ultrasound as safely practiced in medicine. The prudent use of ultrasound and CEUS imaging, including the application of the ALARA (as low as reasonably achievable) principle, should continue to the benefit of patients.
Safety of CEUS Imaging
It has been recognized for years that there are finite risks associated with the use of contrast media in medical imaging. For example, the adverse reaction rates of intravenous CT contrast agents are 4% to 12% for ionic contrast and 1% to 3% for nonionic. 21 For ultrasound contrast agents, the most common effects are headache, a warm sensation, and flushing, all of which resolve in a short time. More unusual events such as nausea, dizziness, chills, altered taste, and chest pain occur in 0% to 5% of patients at a rate similar to that seen in placebo groups. 22 Note that in postmarketing surveillance, the serious adverse event rate for gadolinium diethylenetriaminepentaacetic acid in MR imaging was found to be 1 to 2 per 100,000. 23 Considering the most extreme effects, the death rate from intravenous CT contrast agents is 1 to 3 per 100,000 (0.002%). 21 Only 3 deaths in approximately 160,000 doses were reported in conjunction with current ultrasound contrast agent use, all associated with 1 agent. However, continued use of this agent with changes in contraindications has yielded no additional fatalities, and debate remains as to the role of the agent in the previous deaths. No deaths have been attributed to the other agents in clinical use in the United States and elsewhere. The total number of doses for all ultrasound contrast agents combined is now almost 2 million. Therefore, the death rate associated with ultrasound contrast agents is likely significantly less than that from CT contrast agents.
Obviously these are investigations of commonly found adverse effects, and further study would be needed to follow any potential adverse effects unique to ultrasound contrast agents. However, the general safety profile is as good as or better than that of other imaging agents that are routinely used and currently deemed as acceptable risks given the benefits to the patient.
Guidance for Clinical Trials
As with any ultrasound procedure, the ALARA principle should be followed; that is, one should use only the ultrasound output power level and contrast agent dose needed for diagnostic efficacy. In terms of ultrasound exposure, the advent of low-MI imaging has significantly reduced the requisite pulse amplitude for optimal contrast imaging. Information from bioeffects studies in animals has generally found a threshold for effects at an MI of approximately 0.4, generally higher than those typically used for low-MI imaging. This might serve as some guidance in CEUS imaging studies; however, again the specific need for higher output levels to achieve diagnostic information may be justified. For example, higher levels of acoustic power may be required on the basis of patient factors such as obesity or a deeply located lesion or if the contrast is to be eliminated from the imaging field to measure contrast flow dynamics into a lesion. In any case, the lowest level of acoustic output necessary has always been a guiding principle in medical ultrasound, and this is unchanged when considering the use of CEUS imaging.
The lack of availability of CEUS imaging for noncardiac applications in the United States denies patients a beneficial procedure, resulting in other forms of risk.
V. Training
The AIUM recognizes the importance of proper qualifications of investigators and blinded readers who participate in clinical trials of CEUS. Proper experience and training are important for ultrasound imaging professionals to participate in clinical trials using ultrasound contrast agents. Although the use of contrast media requires unique skills that may not be possessed by many professionals in the United States, these skills are not difficult to learn provided the professionals have a minimum level of knowledge and experience in clinical ultrasound applications. Participation in such a program is intended to ensure a standard skill set for the purposes of the clinical trial and is not necessary after contrast agent approval, although appropriate training should be obtained by those performing clinical CEUS.
Training cases are recommended before enrolling subjects. In addition, qualified study personnel familiar with both imaging technology and contrast agent procedures should serve as onsite monitors to ensure the quality of patient examinations. Two training program models are shown in "Appendix C."
VI. Conclusion
The AIUM believes that implementation of these recommendations will decrease variance among sites and increase the likelihood of successful clinical trials. 
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